A Rollover Study to Provide Continued Treatment With Eltrombopag
Status:
Active, not recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
This study will provide continued access to treatment with eltrombopag for subjects who are
currently participating in a GlaxoSmithKline (GSK) sponsored investigational study of
eltrombopag (parent study) and to collect long term safety data.